Privia Health Group Stock Price Drops 6.3%

Analysts cite concerns over the company's performance and outlook

Jan. 29, 2026 at 10:15pm

Got story updates? Submit your updates here. ›

Privia Health Group, Inc. (NASDAQ:PRVA) saw its stock price decline by 6.3% during trading on Tuesday, with shares trading as low as $22.39 before closing at $22.57. Trading volume was down 61% from the average session, with 241,484 shares changing hands. The drop comes as several research analysts have adjusted their ratings and price targets for the healthcare technology company.

Why it matters

Privia Health Group is a key player in the physician enablement and population health management space, partnering with independent medical practices and health systems. Its stock performance is closely watched as an indicator of the company's financial health and growth prospects within the evolving healthcare landscape.

The details

The stock price decline follows Privia Health Group's latest earnings report, in which the company reported Q4 earnings that beat expectations. However, some analysts have expressed concerns about the company's outlook, leading to adjustments in their ratings and price targets. Weiss Ratings maintained a 'hold (c)' rating on the stock, while Evercore ISI raised its price target from $28 to $30 and reiterated an 'outperform' rating. Truist Financial also reiterated a 'buy' rating but increased its price target from $30 to $31.

  • Privia Health Group's stock price traded down 6.3% during trading on Tuesday, January 30, 2026.

The players

Privia Health Group, Inc.

A physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care.

Weiss Ratings

A research firm that maintained a 'hold (c)' rating on Privia Health Group's stock.

Evercore ISI

An investment research firm that raised its price target for Privia Health Group from $28 to $30 and reiterated an 'outperform' rating.

Truist Financial

A financial services company that reiterated a 'buy' rating on Privia Health Group but increased its price target from $30 to $31.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Privia Health Group's stock performance reflects ongoing concerns about the company's outlook, despite its recent earnings beat. As the healthcare industry continues to evolve, Privia's ability to navigate the changing landscape and deliver value to its physician partners will be closely watched by investors and analysts.